The prognostic impact of soluble and vesicular HLA-G and its relationship to circulating tumor cells in neoadjuvant treated breast cancer patients

Human Immunology

Volumn 77, Issue 9, 2016, Pages 791-799

  König, Lisa ^a   Kasimir Bauer, Sabine ^a   Hoffmann, Oliver ^a   Bittner, Ann Kathrin ^a   Wagner, Bettina ^a   Manvailer, Luis Felipe Santos ^a,b   Schramm, Sabine ^a   Bankfalvi, Agnes ^a   Giebel, Bernd ^a   Kimmig, Rainer ^a   Horn, Peter A ^a   Rebmann, Vera ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b MINISTRY OF EDUCATION OF BRAZIL   (Brazil)

Author keywords

Breast cancer; Extracellular vesicles; Neoadjuvant chemotherapy; Prognostic impact; sHLA G

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CD63 ANTIGEN; CD81 ANTIGEN; CD9 ANTIGEN; CYCLOPHOSPHAMIDE DERIVATIVE; ESTROGEN RECEPTOR; EXOQUICK REAGENT; FLUOROURACIL; GONADORELIN DERIVATIVE; HLA G ANTIGEN; LAPATINIB; METHOTREXATE DERIVATIVE; REAGENT; SOLUBLE HLA G ANTIGEN; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; TUMOR MARKER; TUMOR SUSCEPTIBILITY GENE 101 PROTEIN; UNCLASSIFIED DRUG; VESICULAR HLA G ANTIGEN; PLASMA PROTEIN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STEM CELL; CANCER SURGERY; CANCER SURVIVAL; CIRCULATING TUMOR CELL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXOSOME; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; RETROSPECTIVE STUDY; SURVIVAL PREDICTION; ADOLESCENT; BREAST NEOPLASMS; CARCINOMA, DUCTAL; COMPARATIVE STUDY; DISEASE COURSE; MEMBRANE MICROPARTICLE; METABOLISM; MIDDLE AGED; NEOADJUVANT THERAPY; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME; TUMOR EMBOLISM; TUMOR ESCAPE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD PROTEINS; BREAST NEOPLASMS; CARCINOMA, DUCTAL; CELL-DERIVED MICROPARTICLES; DISEASE PROGRESSION; FEMALE; HLA-G ANTIGENS; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASTIC CELLS, CIRCULATING; NEOPLASTIC STEM CELLS; PROGNOSIS; TREATMENT OUTCOME; TUMOR ESCAPE; YOUNG ADULT;

EID: 84956477189     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2016.01.002     Document Type: Article

References (52)

1. [1] Buchholz, T.A., Hunt, K.K., Whitman, G.J., Sahin, A.A., Hortobagyi, G.N., Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks. Cancer, 98, 2003, 1150.
2. [2] Mauri, D., Pavlidis, N., Ioannidis, J.P., Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J. Natl Cancer Inst., 97, 2005, 188.
3. [3] Bonnefoi, H., Litiere, S., Piccart, M., MacGrogan, G., Fumoleau, P., Brain, E., et al. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial. Ann. Oncol., 25, 2014, 1128.
4. [4] Banys, M., Krawczyk, N., Fehm, T., The role and clinical relevance of disseminated tumor cells in breast cancer. Cancers (Basel), 6, 2014, 143.
5. [5] Joosse, S.A., Gorges, T.M., Pantel, K., Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol. Med., 7, 2015, 1.
6. [6] Geraghty, D.E., Koller, B.H., Orr, H.T., A human major histocompatibility complex class I gene that encodes a protein with a shortened cytoplasmic segment. Proc. Natl. Acad. Sci. U.S.A., 84, 1987, 9145.
7. [7] Carosella, E.D., Favier, B., Rouas-Freiss, N., Moreau, P., Lemaoult, J., Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood, 111, 2008, 4862.
8. [8] Ishitani, A., Geraghty, D.E., Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. Proc. Natl. Acad. Sci. U.S.A., 89, 1992, 3947.
9. [9] Contini, P., Ghio, M., Poggi, A., Filaci, G., Indiveri, F., Ferrone, S., et al. Soluble HLA-A, -B, -C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur. J. Immunol., 33, 2003, 125.
10. [10] Amiot, L., Onno, M., Renard, I., Drenou, B., Guillaudeux, T., Le Bouteiller, P., et al. HLA-G transcription studies during the different stages of normal and malignant hematopoiesis. Tissue Antigens, 48, 1996, 609.
11. [11] Rebmann, V., Pfeiffer, K., Passler, M., Ferrone, S., Maier, S., Weiss, E., et al. Detection of soluble HLA-G molecules in plasma and amniotic fluid. Tissue Antigens, 53, 1999, 14.
12. [12] Rebmann, V., Regel, J., Stolke, D., Grosse-Wilde, H., Secretion of sHLA-G molecules in malignancies. Semin. Cancer Biol., 13, 2003, 371.
13. [13] Carosella, E.D., Moreau, P., Lemaoult, J., Rouas-Freiss, N., HLA-G: from biology to clinical benefits. Trends Immunol., 29, 2008, 125.
14. [14] Chen, H.X., Lin, A., Shen, C.J., Zhen, R., Chen, B.G., Zhang, X., et al. Upregulation of human leukocyte antigen-G expression and its clinical significance in ductal breast cancer. Hum. Immunol., 71, 2010, 892.
15. [15] He, X., Dong, D.D., Yie, S.M., Yang, H., Cao, M., Ye, S.R., et al. HLA-G expression in human breast cancer: implications for diagnosis and prognosis, and effect on allocytotoxic lymphocyte response after hormone treatment in vitro. Ann. Surg. Oncol., 17, 2010, 1459.
16. [16] Kleinberg, L., Florenes, V.A., Skrede, M., Dong, H.P., Nielsen, S., McMaster, M.T., et al. Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Arch., 449, 2006, 31.
17. [17] Riteau, B., Faure, F., Menier, C., Viel, S., Carosella, E.D., Amigorena, S., et al. Exosomes bearing HLA-G are released by melanoma cells. Hum. Immunol., 64, 2003, 1064.
18. [18] Gonzalez, A., Alegre, E., Arroyo, A., LeMaoult, J., Echeveste, J.I., Identification of circulating nonclassic human leukocyte antigen G (HLA-G)-like molecules in exudates. Clin. Chem., 57, 2011, 1013.
19. [19] Yu, D.D., Wu, Y., Shen, H.Y., Lv, M.M., Chen, W.X., Zhang, X.H., et al. Exosomes in development, metastasis and drug resistance of breast cancer. Cancer Sci., 106, 2015, 959.
20. [20] Yanez-Mo, M., Siljander, P.R., Andreu, Z., Zavec, A.B., Borras, F.E., Buzas, E.I., et al. Biological properties of extracellular vesicles and their physiological functions. J. Extracell. Vesicles, 4, 2015, 27066.
21. [21] Witwer, K.W., Buzas, E.I., Bemis, L.T., Bora, A., Lasser, C., Lotvall, J., et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J. Extracell. Vesicles, 2, 2013.
22. [22] Ogorevc, E., Kralj-Iglic, V., Veranic, P., The role of extracellular vesicles in phenotypic cancer transformation. Radiol. Oncol., 47, 2013, 197.
23. [23] Rebmann, V., Lemaoult, J., Rouas-Freiss, N., Carosella, E.D., Grosse-Wilde, H., Report of the wet workshop for quantification of soluble HLA-G in Essen, 2004. Hum. Immunol., 66, 2005, 853.
24. [24] AWMF Online – Mammakarzinom der Frau; Diagnostik, Therapie und Nachsorge, http://www.awmf.org/uploads/tx_szleitlinien/032-045OL_l_S3__Brustkrebs_Mammakarzinom_Diagnostik_Therapie_Nachsorge_2012-07.pdf (accessed 28.09.15).
25. [25] AGO Breast Committee – Guidelines Mamma, http://www.ago-online.de/en/guidelines-mamma/march-2015/ (accessed 28.09.15).
26. [26] Sinn, H.P., Schmid, H., Junkermann, H., Huober, J., Leppien, G., Kaufmann, M., et al. Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy. Geburtshilfe Frauenheilkd., 54, 1994, 552.
27. [27] Sokolova, V., Ludwig, A.K., Hornung, S., Rotan, O., Horn, P.A., Epple, M., et al. Characterisation of exosomes derived from human cells by nanoparticle tracking analysis and scanning electron microscopy. Colloids Surf. B – Biointerfaces, 87, 2011, 146.
28. [28] Kasimir-Bauer, S., Hoffmann, O., Wallwiener, D., Kimmig, R., Fehm, T., Expression of stem cell and epithelial–mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res., 14, 2012, R15.
29. [29] ExoCarta – Exosome Protein, RNA and Lipid Database, www.exocarta.org (accessed 28.09.15).
30. [30] Curigliano, G., Criscitiello, C., Gelao, L., Goldhirsch, A., Molecular pathways: human leukocyte antigen G (HLA-G). Clin. Cancer Res., 19, 2013, 5564.
31. [31] Schutt, P., Schutt, B., Switala, M., Bauer, S., Stamatis, G., Opalka, B., et al. Prognostic relevance of soluble human leukocyte antigen-G and total human leukocyte antigen class I molecules in lung cancer patients. Hum. Immunol., 71, 2010, 489.
32. [32] Jeong, S., Park, S., Park, B.W., Park, Y., Kwon, O.J., Kim, H.S., Human leukocyte antigen-G (HLA-G) polymorphism and expression in breast cancer patients. PLoS One, 9, 2014, e98284.
33. [33] Ugurel, S., Rebmann, V., Ferrone, S., Tilgen, W., Grosse-Wilde, H., Reinhold, U., Soluble human leukocyte antigen-G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer, 92, 2001, 369.
34. [34] Boyson, J.E., Erskine, R., Whitman, M.C., Chiu, M., Lau, J.M., Koopman, L.A., et al. Disulfide bond-mediated dimerization of HLA-G on the cell surface. Proc. Natl. Acad. Sci. U.S.A., 99, 2002, 16180.
35. [35] Galindo-Hernandez, O., Gonzales-Vazquez, C., Cortes-Reynosa, P., Reyes-Uribe, E., Chavez-Ocana, S., Reyes-Hernandez, O., et al. Extracellular vesicles from women with breast cancer promote an epithelial–mesenchymal transition-like process in mammary epithelial cells MCF10A. Tumour Biol., 2015.
36. [36] Gonzalez, A., Rebmann, V., LeMaoult, J., Horn, P.A., Carosella, E.D., Alegre, E., The immunosuppressive molecule HLA-G and its clinical implications. Crit. Rev. Clin. Lab. Sci., 49, 2012, 63.
37. [37] Galindo-Hernandez, O., Villegas-Comonfort, S., Candanedo, F., Gonzalez-Vazquez, M.C., Chavez-Ocana, S., Jimenez-Villanueva, X., et al. Elevated concentration of microvesicles isolated from peripheral blood in breast cancer patients. Arch. Med. Res., 44, 2013, 208.
38. [38] Silva, J., Garcia, V., Rodriguez, M., Compte, M., Cisneros, E., Veguillas, P., et al. Analysis of exosome release and its prognostic value in human colorectal cancer. Genes Chromosom. Cancer, 51, 2012, 409.
39. [39] Bovy, N., Blomme, B., Freres, P., Dederen, S., Nivelles, O., Lion, M., et al. Endothelial exosomes contribute to the antitumor response during breast cancer neoadjuvant chemotherapy via microRNA transfer. Oncotarget, 6, 2015, 10253.
40. [40] Yoshioka, Y., Konishi, Y., Kosaka, N., Katsuda, T., Kato, T., Ochiya, T., Comparative marker analysis of extracellular vesicles in different human cancer types. J. Extracell. Vesicles, 2, 2013.
41. [41] Babst, M., MVB vesicle formation: ESCRT-dependent, ESCRT-independent and everything in between. Curr. Opin. Cell Biol., 23, 2011, 452.
42. [42] Greening, D.W., Gopal, S.K., Mathias, R.A., Liu, L., Sheng, J., Zhu, H.J., et al. Emerging roles of exosomes during epithelial–mesenchymal transition and cancer progression. Semin. Cell Dev. Biol., 40, 2015, 60.
43. [43] Provatopoulou, X., Kalogera, E., Sagkriotis, A., Zagouri, F., Nonni, A., Zografos, G.C., et al. Soluble human leukocyte antigen-G expression in patients with ductal and lobular breast malignancy. Anticancer Res., 32, 2012, 1021.
44. [44] Aydogdu, E., Katchy, A., Tsouko, E., Lin, C.Y., Haldosen, L.A., Helguero, L., et al. MicroRNA-regulated gene networks during mammary cell differentiation are associated with breast cancer. Carcinogenesis, 33, 2012, 1502.
45. [45] Lin, A., Zhang, X., Zhou, W.J., Ruan, Y.Y., Xu, D.P., Wang, Q., et al. Human leukocyte antigen-G expression is associated with a poor prognosis in patients with esophageal squamous cell carcinoma. Int. J. Cancer, 129, 2011, 1382.
46. [46] Samuels, S., Ferns, D.M., Meijer, D., van Straalen, J.P., Buist, M.R., Zijlmans, H.J., et al. High levels of soluble MICA are significantly related to increased disease-free and disease-specific survival in patients with cervical adenocarcinoma. Tissue Antigens, 85, 2015, 476.
47. [47] Veit, T.D., Chies, J.A., Switala, M., Wagner, B., Horn, P.A., Busatto, M., et al. The paradox of high availability and low recognition of soluble HLA-G by LILRB1 receptor in rheumatoid arthritis patients. PLoS One, 10, 2015, e0123838.
48. [48] Shiroishi, M., Kohda, D., Maenaka, K., Preparation and crystallization of the disulfide-linked HLA-G dimer. Biochim. Biophys. Acta, 1764, 2006, 985.
49. [49] Rizzo, R., Vercammen, M., van de Velde, H., Horn, P.A., Rebmann, V., The importance of HLA-G expression in embryos, trophoblast cells, and embryonic stem cells. Cell. Mol. Life Sci., 68, 2011, 341.
50. [50] Verloes, A., Van de Velde, H., LeMaoult, J., Mateizel, I., Cauffman, G., Horn, P.A., et al. HLA-G expression in human embryonic stem cells and preimplantation embryos. J. Immunol., 186, 2011, 2663.
51. [51] Naji, A., Rouas-Freiss, N., Durrbach, A., Carosella, E.D., Sensebe, L., Deschaseaux, F., Concise review: combining human leukocyte antigen G and mesenchymal stem cells for immunosuppressant biotherapy. Stem Cells, 31, 2013, 2296.
52. [52] Selmani, Z., Naji, A., Zidi, I., Favier, B., Gaiffe, E., Obert, L., et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells, 26, 2008, 212.